Kineta, Inc. (KA)

0.5581 -0.0732 (-11.60%) At close: 04:00PM EDT

Kineta, Inc.

219 Terry Ave. N
Suite 300
Seattle, WA 98109
United States
206 378 0400
https://kinetabio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Craig W. Philips	President & Secretary	541.67k	N/A	1961
Mr. Keith A. Baker	Chief Financial Officer	485.75k	N/A	1967
Dr. Thierry Guillaudeux Ph.D.	Chief Scientific Officer	N/A	N/A	1968
Gary Gentges	Executive Vice President of Corporate Development	N/A	N/A	N/A
Ms. Pauline Kenny Esq., J.D.	Advisor	349.72k	N/A	1974

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Corporate governance

Kineta, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.